| pubmed-article:9740093 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9740093 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:9740093 | lifeskim:mentions | umls-concept:C1332128 | lld:lifeskim |
| pubmed-article:9740093 | lifeskim:mentions | umls-concept:C0008838 | lld:lifeskim |
| pubmed-article:9740093 | lifeskim:mentions | umls-concept:C1456820 | lld:lifeskim |
| pubmed-article:9740093 | lifeskim:mentions | umls-concept:C0920321 | lld:lifeskim |
| pubmed-article:9740093 | lifeskim:mentions | umls-concept:C1511496 | lld:lifeskim |
| pubmed-article:9740093 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:9740093 | pubmed:dateCreated | 1998-9-21 | lld:pubmed |
| pubmed-article:9740093 | pubmed:abstractText | Tumor necrosis factor (TNF), hyperthermia, and cisplatin have synergistic cytotoxicity against cancer cells in vitro. This combination may be well suited to the regional treatment of peritoneal tumor spread in patients. Continuous hyperthermic peritoneal perfusion (CHPP) is a technique that allows uniform delivery of cytotoxic agents and heat to the peritoneal surface. A Phase I trial of CHPP with TNF and cisplatin was conducted to define the maximum tolerated dose (MTD) for TNF and cisplatin under moderate hyperthermia in the treatment of peritoneal carcinomatosis. | lld:pubmed |
| pubmed-article:9740093 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9740093 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9740093 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9740093 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:9740093 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9740093 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9740093 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9740093 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9740093 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:9740093 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:9740093 | pubmed:author | pubmed-author:BartlettD LDL | lld:pubmed |
| pubmed-article:9740093 | pubmed:author | pubmed-author:CoteEE | lld:pubmed |
| pubmed-article:9740093 | pubmed:author | pubmed-author:ReedEE | lld:pubmed |
| pubmed-article:9740093 | pubmed:author | pubmed-author:AlexanderH... | lld:pubmed |
| pubmed-article:9740093 | pubmed:author | pubmed-author:LeeK BKB | lld:pubmed |
| pubmed-article:9740093 | pubmed:author | pubmed-author:VenzonD JDJ | lld:pubmed |
| pubmed-article:9740093 | pubmed:author | pubmed-author:LibuttiS KSK | lld:pubmed |
| pubmed-article:9740093 | pubmed:author | pubmed-author:BuellJ FJF | lld:pubmed |
| pubmed-article:9740093 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9740093 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:9740093 | pubmed:volume | 83 | lld:pubmed |
| pubmed-article:9740093 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9740093 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9740093 | pubmed:pagination | 1251-61 | lld:pubmed |
| pubmed-article:9740093 | pubmed:dateRevised | 2005-11-17 | lld:pubmed |
| pubmed-article:9740093 | pubmed:meshHeading | pubmed-meshheading:9740093-... | lld:pubmed |
| pubmed-article:9740093 | pubmed:meshHeading | pubmed-meshheading:9740093-... | lld:pubmed |
| pubmed-article:9740093 | pubmed:meshHeading | pubmed-meshheading:9740093-... | lld:pubmed |
| pubmed-article:9740093 | pubmed:meshHeading | pubmed-meshheading:9740093-... | lld:pubmed |
| pubmed-article:9740093 | pubmed:meshHeading | pubmed-meshheading:9740093-... | lld:pubmed |
| pubmed-article:9740093 | pubmed:meshHeading | pubmed-meshheading:9740093-... | lld:pubmed |
| pubmed-article:9740093 | pubmed:meshHeading | pubmed-meshheading:9740093-... | lld:pubmed |
| pubmed-article:9740093 | pubmed:meshHeading | pubmed-meshheading:9740093-... | lld:pubmed |
| pubmed-article:9740093 | pubmed:meshHeading | pubmed-meshheading:9740093-... | lld:pubmed |
| pubmed-article:9740093 | pubmed:meshHeading | pubmed-meshheading:9740093-... | lld:pubmed |
| pubmed-article:9740093 | pubmed:meshHeading | pubmed-meshheading:9740093-... | lld:pubmed |
| pubmed-article:9740093 | pubmed:meshHeading | pubmed-meshheading:9740093-... | lld:pubmed |
| pubmed-article:9740093 | pubmed:meshHeading | pubmed-meshheading:9740093-... | lld:pubmed |
| pubmed-article:9740093 | pubmed:meshHeading | pubmed-meshheading:9740093-... | lld:pubmed |
| pubmed-article:9740093 | pubmed:meshHeading | pubmed-meshheading:9740093-... | lld:pubmed |
| pubmed-article:9740093 | pubmed:meshHeading | pubmed-meshheading:9740093-... | lld:pubmed |
| pubmed-article:9740093 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9740093 | pubmed:articleTitle | A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. | lld:pubmed |
| pubmed-article:9740093 | pubmed:affiliation | Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA. | lld:pubmed |
| pubmed-article:9740093 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9740093 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9740093 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9740093 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9740093 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9740093 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9740093 | lld:pubmed |
